Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma

Andrew C Johns,Matthew T Campbell,Mamie Gao,Andrew W Hahn,Zita Lim,Emily Wang,Jianjun Gao,Amishi Y Shah,Pavlos Msaouel,Nizar M Tannir

DOI: https://doi.org/10.1093/oncolo/oyae037

2024-03-13

The Oncologist

Abstract:Abstract Background Tivozanib has been approved as a third-line or later therapy for advanced renal cell carcinoma based on the TIVO-3 trial, which was conducted before immune checkpoint therapies (ICT), cabozantinib, and lenvatinib/everolimus became incorporated in the current sequential treatment paradigm for advanced clear cell RCC (ccRCC). Methods We performed a retrospective study of patients with advanced ccRCC treated with tivozanib at MD Anderson Cancer Center during 6/2021-7/2023. A blinded radiologist assessed tumor response by RECIST v1.1. We assessed overall response rate (ORR), clinical benefit rate (CBR) [percentage of all treated patients who achieved radiologic response or stable disease (SD) for ≥ 6 months], progression-free survival (PFS), overall survival (OS), and safety. Results Of 30 analyzed patients, 23% had performance status ≥ 2; 47% had International Metastatic RCC Database Consortium (IMDC) poor-risk disease. Median number of prior therapies was 4 (range 1-8). All patients received prior ICT, 87% cabozantinib and 60% lenvatinib ± everolimus. Of 26 evaluable patients, 2 patients had confirmed partial response (ORR 7.7%); 5 patients had SD for ≥ 6 months (CBR 23.3%). Median PFS was 3.8 months (range 0.7-13.9); median OS was 14.1 months (range 0.3-28.5). Fifteen patients (50%) had ≥ 1 treatment-related adverse event (TRAE). There were 6 grade ≥ 3 TRAEs [hypertension, congestive heart failure (3), mucositis, and GI perforation (grade 5)]. Conclusions In this cohort of heavily pretreated patients with advanced ccRCC, tivozanib yielded a modest clinical benefit in a minority of patients who received prior ICT, cabozantinib, and lenvatinib ± everolimus. TRAEs were consistent with previously published reports.

oncology

What problem does this paper attempt to address?

The paper attempts to address the issue of the efficacy, safety, and tolerability of using Tivozanib as a subsequent treatment in patients with advanced clear cell renal cell carcinoma (ccRCC) who have undergone extensive prior therapy.

Specifically, the paper explores whether Tivozanib remains effective under the current treatment paradigm, where drugs such as immune checkpoint inhibitors (ICT), Cabozantinib, and Lenvatinib have been incorporated into the treatment regimen. The study particularly focuses on whether Tivozanib can provide clinical benefits in these patients and analyzes its safety and adverse reactions.